Theravance Biopharma Sells Trelegy Royalty Interest to GSK

Theravance Biopharma ( (TBPH) ) has issued an update.

On May 30, 2025, Theravance Biopharma entered into an agreement with GlaxoSmithKline (GSK) to sell its remaining royalty interest in Trelegy Ellipta for $225 million. This transaction, part of the company’s strategic efforts to maximize shareholder value, follows a previous sale of Trelegy royalty interests in 2022 for $1.1 billion. The deal underscores Theravance Biopharma’s strategy to monetize its assets while retaining rights to potential milestone payments from Royalty Pharma.

The most recent analyst rating on (TBPH) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on Theravance Biopharma stock, see the TBPH Stock Forecast page.

Spark’s Take on TBPH Stock

According to Spark, TipRanks’ AI Analyst, TBPH is a Neutral.

Theravance Biopharma’s stock score reflects ongoing financial challenges, offset by positive momentum from recent earnings reports. While the company’s revenue growth and strategic milestones are encouraging, consistent losses and negative valuations weigh heavily on the score. Technical indicators suggest mild bearish sentiment, impacting the overall outlook.

To see Spark’s full report on TBPH stock, click here.

More about Theravance Biopharma

Theravance Biopharma, Inc. is a pharmaceutical company focused on developing medicines that make a difference in people’s lives. The company has developed FDA-approved YUPELRI for chronic obstructive pulmonary disease (COPD) and is advancing ampreloxetine for symptomatic neurogenic orthostatic hypotension in patients with Multiple System Atrophy. Theravance Biopharma is committed to creating shareholder value through strategic initiatives.

Average Trading Volume: 244,773

Technical Sentiment Signal: Sell

Current Market Cap: $458M

For a thorough assessment of TBPH stock, go to TipRanks’ Stock Analysis page.